|
The Company
Our Strategy
Our People
Scientific Advisory
Board
Our Accomplishments
| |
|
Helping the world breathe easier |
|
|
The Company
AerovectRx Corporation
is an aerosol therapeutic company
providing proprietary dosage-controlled
solutions to the $20 billion inhaled drug
delivery market. Our FDA-cleared AeroCell™
disposable drug cartridge is unique to the
industry and is designed to improve patient
compliance and eliminate cross contamination.
Our device and disposable product platform is
uniquely suited to deliver a wide variety of
vaccine and therapies varying from multiple-use
mass immunizations, specialty pharmaceutical and
personal home care use. The technology was
developed by the U.S. CDC and licensed
exclusively to AerovectRx.
|
|
Strategy
Our near-term strategy is to
commercialize the CDC platform technology and
license the technology for selected drug
delivery markets. We are seeking drug delivery,
pharmaceutical and biotechnology partners with
which to develop inhaled delivery solutions for
vaccines and other needed therapeutics. Longer
term, we seek to develop novel and customs
compounds for delivery as drug/device
combination product offerings using our
technology platform.
|
|
People
Executives and Board
Edward Cannon, Ph.D.,
Chief Executive Officer
Dr. Cannon joined the company as CEO in 2007,
and has a track record of building successful
healthcare companies. Prior to joining
AerovectRx, Dr. Cannon served as President, CEO
and a director of small molecule
biopharmaceutical companies AdipoGenix and
Elixir Pharmaceuticals, a founder, director, and
President Therapeutics Division, of Dyax Corp.,
a public biotherapeutics company, and founder,
director and CSO of Hygeia Sciences, the leading
developer worldwide of monoclonal antibody-based
home diagnostic products. He earned his
doctorate in biochemistry at the University of
Georgia, trained in molecular immunology at
Harvard Medical School and has held faculty
positions at Brandeis University and University
of Massachusetts Medical School.
P. Kathleen Lovell,
Chairman of the Board of Directors
Ms. Lovell is an angel investor and
businesswoman with a mission, serving as
consultant, advisor, and hands-on business
leader, helping early-stage companies refine
their business models, develop their
infrastructure, access capital and attain
profitability. She has served in executive
management, marketing and operational capacities
with a number of life sciences and technology
companies. Ms. Lovell is a member of angel
investment organization
Emergent Growth Fund, LLC.
Matthew H.J. Kim, J.D.,
Founder, Vice President Licensing and Business
Development
Mr.
Kim founded AerovectRx Corporation in 2005 by
exclusively licensing the platform drug delivery
technology from the U.S. Centers for Disease
Control and Prevention (CDC) where he previously
served as Patent Advisor. Prior to founding
AerovectRx as the CDC's first spin-off company,
Mr. Kim has either served as chief intellectual
property counsel or general counsel for various
publicly and privately-held medical device,
therapeutic and drug delivery companies, as
well as for technology and consumer products
companies. Mr. Kim received his Bachelors in
Biology at Washington University in St. Louis
and his Juris Doctorate at Georgia State
University.
Glen Bradley, Ph.D.,
M.B.A.,
Director
Dr. Bradley is a senior corporate
executive with 35 years of industry experience
as former CEO of Ciba Vision now known as
Ciba Novartis and as a director for many start-up
early stage companies and spin-offs.
Thomas Callaway, M.D.,
M.B.A., Director
Dr. Callaway
is the founder and president of Life Science
Partner and
Managing Director of
Georgia Venture Partners. His experience in
disciplines ranging from biotechnology, business
and marketing strategy, venture capital, and
executive search provides the broad platform
from which Life Science Partner serves life
science companies. Dr. Callaway earned a medical
degree from Vanderbilt University School of
Medicine. He holds an MBA and undergraduate
degree from Duke University.
John P.
Richard, MBA, Director
Mr. Richard is a strategic and commercial
development advisor to the biotechnology
industry and managing director of
Georgia Venture Partners. He currently
serves as Chairman of Altus Pharmaceuticals Inc.
(NASDAQ: ALTU), as Senior Business Advisor to
GPC Biotech AG (NASDAQ: GPCB), and as a
consultant to Nomura Phase4 Ventures. He also
serves as a director of Targacept Inc., Zygogen
LLC, and Metastatix Inc.
Jonathan Mow,
MBA, Director
As co-founder of
Corus Pharma, Mr. Mow was an integral member of
the management team that positioned the
company’s aerosol drug pipeline to be acquired
for approximately $420 million by Gilead
Sciences in 2006. He also was an executive with
the respiratory therapeutic company PathoGenesis
Corporation which was acquired by Chiron for
approximately $700 million in 2000. Mr. Mow
previously worked in various strategic planning
and marketing positions at Bristol-Myers Squibb,
Lederle/Wyeth International and Syntex
Laboratories.
David Johnson, Ph.D., Director
Dr. Johnston was
most recently Senior Vice President of Research
and Development for Nektar Therapeutics where
his responsibilities included planning and
operations for drug delivery, including
inhalation technologies, clinical development,
regulatory affairs and safety, quality control
and assurance for clinical supplies, and product
and device development. He has previously held
executive leadership positions with Control
Delivery Systems, AAI International and Oread,
Inc. Dr. Johnston earned his bachelor’s and
doctorate degrees in chemistry from St. Andrews
University (Scotland) and completed postdoctoral
training at the Max Planck Institute
(Heidelberg, Germany).
|
|
Scientific
Advisory Board
The AerovectRx Corporation
board of advisors represents some
of the innovative and dedicated researchers in
the field of respiratory care and aerosol drug
delivery.
Kenneth
Brigham, M.D. (Chair). Dr.
Brigham served as Ralph and Lulu Owen Professor
Pulmonary Medicine and Director of the Center
for Lung Research and the Division of Allergy
Pulmonary and Critical Care Medicine at
Vanderbilt University from 1973 until he joined
the Emory University faculty in 2002 as Vice
Chairman of the Department of Medicine. Dr.
Brigham is also Associate Director for Research
McKelvey Lung Transplantation Center; Director
of a new Center for Translational Research in
the Lung; and Interim Director Predictive Health
Initiative. He is a previous President of the
American Thoracic Society, has chaired several
National Institutes of Health review committees
and served on the editorial board of many
scholarly journals.
Robert
Aris, M.D. Dr. Aris currently serves
as an Associate Professor of Medicine at the
University of North Carolina at Chapel Hill
while also serving as Director at the Pulmonary
Hypertension Clinic and as Director at the Lung
Transplantation Immunology Laboratory. Dr. Aris
has authored or co-authored over 80 publications
on the topic of pulmonary function and lung
disease and has been invited to present at
numerous industry events and serves or has
served on the editorial board of journals such
as CHEST, Current Respiratory Medicine Reviews,
American Journal of Respiratory and Critical
Care Medicine, and The Open Respiratory Medicine
Journal.
James J. Barry, Ph.D.
Dr. Barry is a principal and President of
Creare, Inc., CDC contract recipient and SBIR
and STTR recipient for the development of the
nebulizer technology licensed from the CDC. As
co-inventor of the technology assigned to the
CDC for the nebulizer technology, Dr. Barry
provides necessary know-how and trade secrets to
facilitate AerovectRx’s commercialization of the
technology.
Beth L.
Laube, Ph.D. Dr. Laube holds a Ph.D.
from the Johns Hopkins Bloomberg School of
Public Health in Baltimore, Maryland and is
currently an Associate Professor of Pediatrics
at the Johns Hopkins School of Medicine. Dr.
Laube is President of the International Society
for Aerosols in Medicine (ISAM) and is a member
of the American Thoracic Society. She serves on
the Editorial Board of the Journal of Aerosol
Medicine, on the advisory committee to the World
Health Organization Product Development Group
for the Aerosolized Measles Vaccine Project and
on the National Academy of Science’s Committee
on Animal Models for Testing Interventions
Against Aerosolized Bioterrorism Agents. Dr.
Laube is a frequent advisor to pre-doctoral
candidates and post-doctoral fellows at the
Johns Hopkins University and at the University
of Maryland and has published over 40
peer-reviewed articles.
Ralph
Tripp, Ph.D. Dr.Tripp brings over 17
years of research experience in the field of
influenza and respiratory virology studies and
related intervention experiences. Prior to
becoming a professor at the University of
Georgia veterinary school in the department of
infectious diseases and Vaccine Chair for the
Georgia Research Alliance, Dr. Tripp served at
the Centers for Disease Control as section chief
of the Respiratory and Enteric Viruses Branch.
Gerald
Smaldone, M.D., Ph.D.
Dr. Smaldone is one of the leading experts
in the field of aerosol medicine with numerous
publications, patents, and presentations in this
field. After receiving a Bachelors of
Engineering in Chemical Engineering at New York
University School of Engineering and Science, he
later received his doctorate in medicine as well
as his Ph.D. in Physiology at New York
University School of Medicine. In addition to
his consulting activities, Dr. Smaldone
regularly serves as Chief of the
Pulmonary/Critical Care Division at SUNY Stony
Brook while also teaching as a Professor or
Medicine, Physiology and Biophysics for the
medical school. Dr. Smaldone is an active
member of the International Society for Aerosol
Medicine and is the founding editor of Journal
of Aerosol Medicine.
Arlene
Stecenko, M.D.
Prior to joining the Department of Medicine at
Emory University as Associate Professor of
Medicine in 2002, Dr. Stecenko served on the
Vanderbilt University Faculty as Associate
Professor Medicine. She was formerly Chief of
the Division of Pediatric Pulmonary Medicine at
the University of Florida Medical Center in
Gainesville. She is currently Division Chief,
Pulmonary, Allergy, Cystic Fibrosis and Sleep,
Department of Pediatrics; Director the Emory
University Cystic Fibrosis Center, and
Investigator for the McKelvey Lung
Transplantation Center.
SAB Observer
Mark Papania, MD, M.P.H. Dr. Papania is the primary
inventor for the CDC licensed technology. Dr.
Papania brings over 20 years of experience in
public health and epidemiology with special
emphasis on infectious diseases and measles in
particular.
Members of the AerovectRx Scientific Advisory
Board are compensated for their time and are
independent of the company. Listing of the
affiliated institutions by the respective
members of the Scientific Advisory Board does
not necessarily reflect an endorsement by those
institutions.
Back to
Top |
|
Recent
Accomplishments
Formation of Scientific
Advisory Board
$750,000 contract awarded to
develop inhaled vaccine platform for
influenza
Industrial design and product
engineering for first product launched
Commercial license executed
from CDC
Second generation prototypes
developed and in testing
Toxicology studies with
initial candidate vaccine completed with no
adverse effects
First U.S. Food and Drug
Administration 510(k) clearance to market
issued
|
|
|
|
